Sabina A Antoniu1. 1. University of Medicine and Pharmacy, Pulmonary Disease, University Hospital, Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
Abstract
BACKGROUND: In chronic obstructive pulmonary disease (COPD), inhaled tiotropium bromide, a long-acting anticholinergic, has been shown to exert a sustained bronchodilator effect and to be superior to ipratropium bromide, a short-acting formulation of the same pharmacological class. OBJECTIVE: To discuss the effects of long-term therapy with tiotropium in COPD. METHODS/ RESULTS: Analysis of efficacy and safety data on tiotropium from a 4-year randomized placebo controlled study performed in moderate to very severe COPD patients. Tiotropium was found to reduce significantly COPD-related morbidity, to improve health-related quality of life (HRQoL) irrespective of disease severity and to slow significantly lung function decline in patients not using inhaled corticosteroids or other long-acting bronchodilators. The safety profile -- and in particular cardiovascular safety -- of tiotropium was good. CONCLUSIONS:Tiotropium bromide, alone or in combination with other inhaled therapies, can maintain an adequate control of COPD on a long-term basis.
RCT Entities:
BACKGROUND: In chronic obstructive pulmonary disease (COPD), inhaled tiotropium bromide, a long-acting anticholinergic, has been shown to exert a sustained bronchodilator effect and to be superior to ipratropium bromide, a short-acting formulation of the same pharmacological class. OBJECTIVE: To discuss the effects of long-term therapy with tiotropium in COPD. METHODS/ RESULTS: Analysis of efficacy and safety data on tiotropium from a 4-year randomized placebo controlled study performed in moderate to very severe COPDpatients. Tiotropium was found to reduce significantly COPD-related morbidity, to improve health-related quality of life (HRQoL) irrespective of disease severity and to slow significantly lung function decline in patients not using inhaled corticosteroids or other long-acting bronchodilators. The safety profile -- and in particular cardiovascular safety -- of tiotropium was good. CONCLUSIONS:Tiotropium bromide, alone or in combination with other inhaled therapies, can maintain an adequate control of COPD on a long-term basis.
Authors: David W Brown; Roy Pleasants; Jill A Ohar; Monica Kraft; James F Donohue; David M Mannino; Winston Liao; Harry Herrick Journal: N Am J Med Sci Date: 2010-02
Authors: Javed H Khan; Hani M S Lababidi; Mohamed S Al-Moamary; Mohammed O Zeitouni; Hamdan H Al-Jahdali; Omar S Al-Amoudi; Siraj O Wali; Majdy M Idrees; Abdullah A Al-Shimemri; Mohammed O Al Ghobain; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2014-04 Impact factor: 2.219
Authors: Stinna Skaaby; Esben Meulengracht Flachs; Peter Lange; Vivi Schlünssen; Jacob Louis Marott; Charlotte Brauer; Børge G Nordestgaard; Steven Sadhra; Om Kurmi; Jens Peter Ellekilde Bonde Journal: PLoS One Date: 2020-12-28 Impact factor: 3.240